Boston Receives FDA Approval for PROMUS Element™ Plus Galaxy Stocks Boston Scientific Corporation has recently announced that it has won approval from US Food and Drug Administration (FDA) for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company's next-generation drug ... |
